Lumiflavin

Lumiflavin

SCHEMBL193713

Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C)c2cc1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.76
KMT2A Q03164 7/20 0.76
MAPT P10636 3/20 0.76
RECQL P46063 3/20 0.76
TDP2 O95551 2/20 0.76
NGF P01138 1/20 0.76
NTRK1 P04629 1/20 0.76
BLM P54132 1/20 0.76
KDM4E B2RXH2 5/20 0.60
USP2 O75604 4/20 0.60
HTT P42858 3/20 0.60
TDP1 Q9NUW8 2/20 0.60
RXFP1 Q9HBX9 2/20 0.60
IDO1 P14902 1/20 0.60
HAT1 O14929 4/20 0.55
RBBP7 Q16576 4/20 0.55
ALDH1A1 P00352 3/20 0.55
CASP1 P29466 2/20 0.55
BRCA1 P38398 2/20 0.55
CASP7 P55210 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lumiflavin SCHEMBL29516802 1.00 MEN1 (0.76) MEN1KMT2AMAPTRECQLTDP2
Lumiflavin SCHEMBL6365933 0.98 MEN1 (0.74) MEN1KMT2AMAPTRECQLTDP2
Lumiflavin SCHEMBL6373617 0.97 MEN1 (0.72) MEN1KMT2AMAPTRECQLTDP2
SCHEMBL864918 0.89 MEN1 (0.69) MEN1KMT2AMAPTRECQLTDP2
SCHEMBL9022677 0.89 MEN1 (0.69) MEN1KMT2AMAPTRECQLTDP2
SCHEMBL16557144 0.86 MEN1 (0.66) MEN1KMT2AMAPTRECQLTDP2
SCHEMBL15683182 0.86 MEN1 (1.00) MEN1KMT2AMAPTRECQLTDP2
SCHEMBL10285873 0.86 MEN1 (0.66) MEN1KMT2AMAPTRECQLTDP2
SCHEMBL29375964 0.86 MEN1 (1.00) MEN1KMT2AMAPTRECQLTDP2
SCHEMBL13955810 0.85 MEN1 (0.61) MEN1KMT2AMAPTRECQLTDP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 928 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12571758-B2 Glucose redox reaction and composition for glucose measurement using flavin compound KIKKOMAN CORPORATION (JP) 2026-03-10 US claimed
US-20250362307-A1 PHOTOACTIVE ANTIBODY CONJUGATE LIAO JUNG CHI (TW) 2025-11-27 US claimed
US-12376601-B2 Systems and method for removing the yellow color of riboflavin from lactose solutions SPX FLOW TECHNOLOGY DANMARK A/S (DK) 2025-08-05 US claimed
EP-3976197-B1 THERAPEUTICS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER LUNELLA BIOTECH INC (CA) 2025-07-16 EP claimed
EP-3934594-B1 ENERGY AUGMENTATION STRUCTURES FOR USE IN NON-INVASIVE IN-SITU PHOTOBIOMODULATION IMMUNOLIGHT LLC (US) 2025-05-28 EP claimed
US-20250143897-A1 STENT-CONTAINING MEDICAL DEVICES AND METHODS OF USING THE SAME BOSTON SCIENTIFIC SCIMED, INC. (US) 2025-05-08 US claimed
EP-4473309-A1 PHOTOACTIVE ANTIBODY CONJUGATE Syncell (Taiwan) Inc. (TW) 2024-12-11 EP claimed
EP-3367890-B1 A PHOTOACTIVATABLE DRUG FOR USE IN RADIOTHERAPY IMMUNOLIGHT LLC (US) 2024-12-04 EP claimed
US-12121746-B2 Energy augmentation structures, energy emitters or energy collectors containing the same, and their use in methods and systems for treating cell proliferation disorders IMMUNOLIGHT, LLC (US) 2024-10-22 US claimed
US-11992697-B2 X-ray psoralen activated cancer therapy (X-PACT) IMMUNOLIGHT, LLC 2024-05-28 US claimed
EP-1047458-A2 METHOD FOR INACTIVATION OF MICROORGANISMS USING PHOTOSENSITIZERS Gambro, Inc., (US) 2000-11-02 EP claimed
WO-2000004930-A2 METHOD FOR INACTIVATION OF MICROORGANISMS USING PHOTOSENSITIZERS GAMBRO, INC. (US) 2000-02-03 WO claimed
WO-2000004210-A2 CMOS COMPATIBLE IDENTIFICATION OF PROCESS FLUIDS ROBERT BOSCH GMBH (DE) 2000-01-27 WO claimed
US-5834198-A PHOTOOXIDATION BOEHRINGER MAMNNHEIM GMBH (DE) 1998-11-10 US claimed
EP-0801072-A2 Selective photoinduced flavin-dependent cleavage of rna at g-u base pairs Roche Diagnostics GmbH (DE) 1997-10-15 EP claimed
EP-0739208-A1 FLAVIN DERIVATIVES AS ANTI-VIRAL AGENTS RADOPATH LIMITED (GB) 1996-10-30 EP claimed
WO-1995011028-A1 FLAVIN DERIVATIVES AS ANTI-VIRAL AGENTS RADOPATH LIMITED (GB) 1995-04-27 WO claimed
WO-1993010784-A1 THERAPEUTIC COMPOSITION AND METHOD FOR PREVENTING REPERFUSION INJURY UNIVERSITY OF MICHIGAN (US) 1993-06-10 WO claimed
US-5153236-A Comprising an N-aryl-alpha-amino acid and a photosensitizer such as a thixoanthone, isoalloxazine or coumarine; high sensitivity to UV and visible light; storage stability; photoresists; relief images HITACHI CHEMICAL CO., LTD. (JP) 1992-10-06 US claimed
US-4749670-A Selective regeneration of mediators in the presence of a catalyst and surfactant BASF AKTIENGESELLSCHAFT (DE) 1988-06-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12571758-B2 Glucose redox reaction and composition for glucose measurement using flavin compound G6PD, TKFC, UGDH MEN1 3734/4885KMT2A 3438/4885MAPT 1740/4885
US-12121746-B2 Energy augmentation structures, energy emitters or energy collectors containing the same, and their use in methods and systems for treating cell proliferation disorders TK2, GFM1, HDGF MEN1 1291/4885KMT2A 4191/4885MAPT 3685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.